AUSTIN, Texas, Feb. 24, 2021 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare metabolic diseases,
today announced the appointment of Sara
Brownstein to its board of directors. Ms. Brownstein serves
as a principal at Baker Bros. Advisors LP.
"I am very pleased to welcome Sara to our board of directors at
this important stage in Aeglea's evolution as we work towards
several important milestones for the company – including topline
data from our pivotal Phase 3 clinical trial of pegzilarginase for
the treatment of Arginase 1 Deficiency and dosing the first patient
in our Phase 1/2 clinical trial of AGLE-177 for the treatment of
Homocystinuria," said Anthony Quinn,
M.B Ch.B, Ph.D., president and chief executive officer of Aeglea.
"Sara brings a broad and distinct perspective from more than a
decade of life science investing and company building. Her
experience and acumen are a valuable addition to our Board, as we
move closer to our goal of delivering impactful medicines for
patients living with rare metabolic diseases."
Prior to joining Baker Bros. Advisors LP, Ms. Brownstein worked
for Goldman, Sachs & Co. Ms. Brownstein graduated from the
University of Pennsylvania's Jerome
Fisher Program in Management and Technology, obtaining a BAS in
Biomedical Science (School of Engineering and Applied Science) and
a B.S. in Economics (Wharton School). She currently serves on
the board of directors of Levo Therapeutics, Inc.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and devastating metabolic diseases with limited
treatment options. Aeglea's lead product candidate, pegzilarginase,
is in a pivotal Phase 3 trial for the treatment of Arginase 1
Deficiency and has received both Rare Pediatric Disease and
Breakthrough Therapy Designation. In the second quarter of 2020,
the Company initiated a Phase 1/2 clinical trial of AGLE-177 for
the treatment of Homocystinuria. AGLE-177 has also been granted
Rare Pediatric Disease Designation. Aeglea has an active discovery
platform focused on engineering small changes in human enzymes to
have a big impact on the lives of patients and their families. For
more information, please visit http://aeglea.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, statements we
make regarding the potential addressable markets of our product
candidates, the timing and success of our clinical trials and
related data, the timing and expectations for regulatory
submissions and approvals, timing and results of meetings with
regulators, the timing of announcements and updates relating to our
clinical trials and related data, our ability to enroll patients
into our clinical trials, the expected impact of the COVID-19
pandemic on our operations and clinical trials, success in our
collaborations, our cash forecasts, and the potential
therapeutic benefits and economic value of our lead product
candidate or other product candidates. Further information on
potential risk factors that could affect our business and its
financial results are detailed in our most recent Quarterly Report
on Form 10-Q for the quarter ended September
30, 2020 filed with the Securities and Exchange Commission
(SEC), and other reports as filed with the SEC. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-appoints-sara-brownstein-to-board-of-directors-301234970.html
SOURCE Aeglea BioTherapeutics, Inc.